



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



C8 Galactosylceramide (d18:1/8:0)

Item No. 24346

CAS Registry No.: 41613-16-5

Formal Name: N-[(1S,2R,3E)-1-[(β -D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-octanamide

Synonyms: Galactosylceramide (d18:1/8:0), N-octanoyl- β -D-Galactosylceramide, GalCer(d18:1/8:0)

MF: C₃₂H₆₁NO₈

FW: 587.8


Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

C8 Galactosylceramide (d18:1/8:0) is supplied as a solid. A stock solution may be made by dissolving the C8 galactosylceramide (d18:1/8:0) in the solvent of choice. C8 Galactosylceramide (d18:1/8:0) is soluble in ethanol and methanol and a 9:1 solution of chloroform:methanol.

Description

C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids.¹ It increases the amount delivered and toxicity of doxorubicin (Item No. 15007) in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes *in vitro* at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production *in vivo*.² It also activates NF- κ B production in C6 glioma cells when used at a concentration of 10 μ M.³

References

1. Pedrosa, L.R., van Hell, A., Süss, R., et al. Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids. *Pharm. Res.* **30**(7), 1883-1895 (2013).
2. Parekh, V.V., Singh, A.K., Wilson, M.T., et al. Quantitative and qualitative differences in the *in vivo* response of NKT cells to distinct α - and β -anomeric glycolipids. *J. Immunol.* **173**(6), 3693-3706 (2004).
3. Chang, Y.-T., Choi, J., Ding, S., et al. The synthesis and biological characterization of a ceramide library. *J. Am. Chem. Soc.* **124**(9), 1856-1857 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM